Avalo Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AVTX Nasdaq 2836 www.avalotx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avalo Therapeutics, Inc.

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer - Jan 2nd, 2025 12:00 pm
Avalo Therapeutics initiated with a Buy at BTIG - Dec 20th, 2024 11:50 am
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - Nov 12th, 2024 12:00 pm
Avalo Therapeutics to Present at Upcoming Investor Conferences - Nov 11th, 2024 12:00 pm
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates - Nov 7th, 2024 12:00 pm
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - Oct 8th, 2024 11:00 am
Avalo Announces Participation in September Investor Conferences - Sep 4th, 2024 11:00 am
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates - Aug 12th, 2024 11:00 am
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer - Jul 16th, 2024 11:00 am
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa - Jul 9th, 2024 11:00 am
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer - Jun 24th, 2024 8:01 pm
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit - Jun 17th, 2024 11:30 am
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates - May 13th, 2024 11:30 am
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors - Apr 2nd, 2024 11:00 am
Avalo Reports 2023 Financial Results and Provides Business Updates - Mar 29th, 2024 8:01 pm
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million - Mar 27th, 2024 8:01 pm